Log In
Print
BCIQ
Print
Print this Print this
 

Suglat, ipragliflozin (ASP1941)

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Japan - Standard Review (Treat Type II diabetes)

Partner

Kotobuki Pharmaceutical Co.; Merck & Co. Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today